Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study

被引：9
|
作者：
Luebbert, Michael [1 ]
Rueter, Bjorn [1 ]
Claus, Rainer
Schmid, Mathias [2 ]
Germing, Ulrich [3 ]
Eimeracher, Hartmut [4 ]
Ganser, Arnold [5 ]
Platzbecker, Uwe [6 ]
Galm, Oliver [7 ]
Brugger, Wolfram [8 ]
Heil, Gerhard [9 ]
Wijermans, Pierre W. [10 ]
Pfeifer, Dietmar [1 ]
Schmoor, Claudia [11 ]
Doehner, Hartmut [2 ]
机构：
[1] Univ Hosp, Freiburg, Germany
[2] Univ Hosp, Ulm, Germany
[3] Univ Hosp, Dusseldorf, Germany
[4] Catholic Hosp, Hagen, Germany
[5] Univ Hosp, Hannover, Germany
[6] Univ Hosp, Dresden, Germany
[7] Univ Hosp, Aachen, Germany
[8] Hospital, Villigen Schwenningen, Germany
[9] Hospital, Ludenscheid, Germany
[10] Leyenburg Hosp, The Hague, Netherlands
[11] Univ Hosp, Ctr Clin Trials, Freiburg, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.300.300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：95A / 95A
页数：1
相关论文
共 50 条
  • [31] Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study
    José Luis Firvida
    Margarita Amenedo
    Rubén Rodríguez
    Ana González
    Mercedes Salgado
    Manuel Ramos
    Gustavo Losada
    Investigational New Drugs, 2004, 22 : 481 - 487
  • [32] Erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC): preliminary results from a multicenter phase II study
    Milella, M.
    Sperduti, I.
    Gelibter, A.
    Bria, E.
    Cianci, G.
    Moscetti, L.
    Mansueto, G.
    Ruggeri, E. M.
    Gamucci, T.
    Cognetti, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 389 - 389
  • [33] Phase II Study of Low-dose Everolimus Plus Weekly Cisplatin and 24-hour Infusion of High-dose 5-fluorouracil and Leucovorin for First-line Treatment of Metastatic or Recurrent Gastric Cancers
    Yeh, K.
    Shen, Y. C.
    Li, C. P.
    Yen, C. J.
    Lin, Y. L.
    Lin, Z. Z.
    Chen, L. T.
    Su, W. C.
    Chao, Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S467 - S467
  • [34] Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results
    Uy, Geoffrey L.
    Pullarkat, Vinod A.
    Baratam, Praneeth
    Stuart, Robert K.
    Faderl, Stefan
    Chandrasekaran, Vijayalakshmi
    Wang, Qi
    Chakravarthy, Divya
    Cheung, Ronald S.
    Lin, Tara L.
    BLOOD, 2021, 138
  • [35] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: preliminary results from an open-label, multicenter phase II study
    Song, Hong Suk
    Do, Young Rok
    Chang, Heung Moon
    Ryu, Min Hee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Hong, Dae Sik
    Cho, Jae Yong
    Lee, Kyoung Eun
    Kim, Si Young
    ANNALS OF ONCOLOGY, 2004, 15 : 243 - 243
  • [36] A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
    Yokoyama, Toshihide
    Yoshioka, Hiroshige
    Fujimoto, Daichi
    Demura, Yoshiki
    Hirano, Katsuya
    Kawai, Takahiro
    Kagami, Ryogo
    Washio, Yasuyoshi
    Ishida, Tadashi
    Kogo, Mariko
    Tomii, Keisuke
    Okuno, Takehiro
    Akai, Masaya
    Hirabayashi, Masataka
    Nishimura, Takashi
    Nakahara, Yasuharu
    Kim, Young Hak
    Miyakoshi, Chisato
    Yoshimura, Kenichi
    Hirai, Toyohiro
    LUNG CANCER, 2019, 135 : 175 - 180
  • [37] Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
    Heidel, Florian
    Cortes, Jorge
    Ruecker, Frank G.
    Aulitzky, Walter
    Letvak, Laurie
    Kindler, Thomas
    Huber, Christoph
    Doehner, Hartmut
    Kantarjian, Hagop
    Fischer, Thomas
    CANCER, 2007, 109 (05) : 907 - 914
  • [38] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
    M Campone
    H Cortes-Funes
    D Vorobiof
    M Martin
    C F Slabber
    E Ciruelos
    E Bourbouloux
    C Mendiola
    F M Delgado
    C Colin
    V Aslanis
    P Fumoleau
    British Journal of Cancer, 2006, 95 : 1161 - 1166
  • [39] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
    Campone, M.
    Cortes-Funes, H.
    Vorobiof, D.
    Martin, M.
    Slabber, C. F.
    Ciruelos, E.
    Bourbouloux, E.
    Mendiola, C.
    Delgado, F. M.
    Colin, C.
    Aslanis, V.
    Fumoleau, P.
    BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1161 - 1166
  • [40] DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
    Olga Grishina
    Claudia Schmoor
    Konstanze Döhner
    Björn Hackanson
    Beate Lubrich
    Annette M. May
    Caroline Cieslik
    Michael J. Müller
    Michael Lübbert
    BMC Cancer, 15
12345